Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ALKS 8700 capsules
Study Drug · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Study Drug | EXPERIMENTAL | Oral capsules |
| Active Control | ACTIVE_COMPARATOR | Oral capsules |
| Placebo | PLACEBO_COMPARATOR | Oral capsules |
| Name | Type | Description |
|---|---|---|
| Study Drug | DRUG | - |
| Active Control | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Has a body-mass Index (BMI) \>/=18.0 and \</=32.0 kg/m2 * Agrees to use an acceptable method of contraception for the duration of the study and for 30 days after any study drug administration * Additional criteria may apply Exclusion Criteria: * Is currently pregnant or brea...
Top 17 of 21 competitors
Study Drug is an investigational small molecule developed by Biogen Inc. for multiple sclerosis, a neurological condition. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. It is not described as approved, so it remains in clinical development.
Study Drug is being developed for multiple sclerosis, a neurological disease. The completed Phase 1 study enrolled healthy adult volunteers rather than patients with multiple sclerosis, so the program is at an early stage of clinical development. No approved use has been established.
Biogen Inc., which trades under the ticker BIIB, is the developer of Study Drug. The company sponsored the Phase 1 trial of the asset in multiple sclerosis. Biogen is the named developer associated with this program.
Study Drug is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are listed. Because the program is at this early stage, Study Drug is investigational and has not been established as an approved therapy for multiple sclerosis.
Study Drug has been evaluated in one completed Phase 1 trial, NCT02201849, titled A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults. The trial enrolled 104 participants in the United States, was randomized, double blind, and placebo controlled, and used healthy volunteers aged 18 years and older.
Yes. Study Drug is also known as ALKS 8700, a monomethyl fumarate (MMF) molecule. The Phase 1 trial NCT02201849 was conducted under the ALKS 8700 name in healthy adults. Searches for either name refer to the same Biogen multiple sclerosis asset.